IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
September 2021 Vol.:22, Issue:2
© All rights are reserved by Shah Divya H.et al.

Niosomal Drug Delivery System

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Shah Divya H.*, Patel Mansi M., Chainesh Shah, Mitali Dalwadi, Umesh Upadhyay

Sigma Institute Of Pharmacy, Bakrol, Vadodara-390019. India.

Submitted: 22 August 2021
Accepted: 27 August 2021
Published: 30 September 2021

HUMAN JOURNALS
www.ijppr.humanjournals.com

Keywords: Niosome, peptide drug, drug targeting, bioavailability improvement

ABSTRACT

Niosome is non-ionic surfactant vesicles got by a hydrating combination of cholesterol and nonionic surfactants. It tends to be utilized as transporters of an amphiphilic and lipophilic drugs. In the niosomes drug delivery system, the medicine is epitomized in a vesicle. Niosomes are biodegradable, biocompatible non-immunogenic, and display adaptability in their primary portrayal. The primary object of this audit the utilization of niosome innovation is utilized to treat various illnesses, niosome have great freedom in research and advantageous for analyst and pharma enterprises. Niosome has all the earmarks of being an all-around favored drug delivery system over liposome as niosome being steady and monetary. Likewise, niosomes have incredible drug delivery potential for designated delivery of hostile to malignant growth, against infective specialists. The drug delivery capability of niosome can upgrade by utilizing novel drug delivery ideas like proniosomes, discomes, and aspasome. Niosomes additionally serve better guide in demonstrative imaging and as an antibody adjuvant. Accordingly, these regions need further investigation and exploration to bring out or to make for financially accessible niosomal arrangements.

INTRODUCTION [1-8]

Niosomes are an original drug delivery system, which captured the hydrophilic drug in the center pit and hydrophobic drugs in the non-polar locale present inside the bilayer subsequently both hydrophilic and hydrophobic drugs can be joined into niosomes. The niosomes are amphiphilic, in which the medicine is exemplified in a vesicle which is made by non-ionic surfactant and thus the name niosomes. The niosomes size is tiny and minute. The first niosome details were created and licensed by L'Oreal in 1975. Within the sight of appropriate combinations of surfactants and charge actuating specialists from the thermodynamically steady vesicles. Niosomes are generally concentrated as an option in contrast to liposomes since they reduce the burdens related to liposomes. Niosomes defeat the hindrances related to liposomes like substance flimsiness. The synthetic precariousness of liposomes is because of their inclination to oxidative corruption and variable immaculateness of phospholipids. The primary reason for creating niosomal system is compound soundness, biodegradability, biocompatibility, substance strength, low creation cost, simple stockpiling and taking care of and low poisonousness. Niosomes can be administrated through different courses like oral, parenteral, effective. Niosomes are utilized as a transporter to convey various kinds of drugs like manufactured and natural, antigens, chemicals, and other bioactive mixtures. This article presents some Salient elements of niosomes alongside an outline of the readiness procedures and the current utilizations of niosomes in encapsulation and delivery of bioactive mixtures.



Figure No. 1: Niosomes

NOTABLE PROVISIONS OF NIOSOMES [9-13]

- Niosomes can capture solutes.
- Niosomes are osmotically dynamic and stable.
- Niosomes have an infra-structure involving hydrophobic and hydrophilic generally together hence similarly oblige the medicine particles with a broad assortment of dissolvability.
- Niosome release the drug in a controlled manner through its bilayer which gives upheld appearance of the encased medicine, so niosomes fill in as prescription distribution center in the body.
- Targeted drug movement can moreover be cultivated using niosomes the medicine is passed on explicitly to the body part where the healing effect is required. Thereby diminishing the estimation needed to be figured out how to achieve the desired effect.
- They work on the dissolvability and oral bioavailability of inadequately solvent drugs and improve the skin penetrability of drugs when applied topically.
- Niosomes display adaptability in their primary attributes (creation, ease, and size) and can be planned by the ideal circumstance.
- Niosomes can work on the presentation of the drug atoms.
- Better accessibility to the specific site, just by shielding the drug from natural climate.
- Niosomes increment the steadiness of the captured drug.

BENEFITS [15-18]

- **Bioavailability Improvement:** The term bioavailability insinuates the piece of a dose that is available at the site of movement in the body. Niosomes have indisputable inclinations over standard plans sin1ce the vesicles can go about as drug stores and safeguards calm from acidic and enzymatic corruption in the gastro-digestive system which achieves bioavailability improvement and extended the ability to cross the physical deterrent of the gastrointestinal parcel.

- They improve the therapeutic execution of the drug particles by delayed space from the dispersal, protecting the prescription from the regular condition, and restricting effects on track cells.

- Niosomal scattering in a fluid stage can be emulsified in a nonwatery stage to direct the delivery.

- Rate of drug and manage ordinary vesicle in the outside non-watery stage.

- They are osmotically dynamic and stable, just as they increment the security of entangled drugs.

- Handling and capacity of surfactants requires no exceptional conditions.

- They work on the oral bioavailability of inadequately assimilated drugs and improve skin entrance of drugs.

- They can be made to arrive at the site of activity by oral, parenteral just as effective courses.

KINDS OF NIOSOMES [19-21]

- **Bola surfactant comprising niosomes**

The surfactant used in Bola surfactant-containing niosomes are made of omega hexadecylbis-(1-aza-18 crown-6) (bola surfactant): range 80/cholesterol in 2:3:1molar proportion.

- **Proniosomes**

Proniosomes are produced using the transporter and surfactant combination.

After the hydration of proniosomes, Niosomes are delivered.

- **Aspasomes**

Aspasomes are created utilizing the blend of ascorbyl palmitate, cholesterol, and outstandingly charged lipid diacetyl phosphate prompts the plan of vesicles. Aspasomes are first hydrated with water/liquid plan and a while later it is exposed to sonication to get the niosomes. Aspasomes can be used to assemble the transdermal immersion of prescriptions. Aspasomes have similarly been used to lessen disperse brought about by responsive oxygen species as it has natural cell support property.



Figure No. 2: Types of Niosomes

METHODS OF NIOSOMES [22-31]

Ether infusion strategy

Ether infusion strategy is founded on leisurely presenting an answer of surfactant broke down in diethyl ether into warm water kept up with at 60°C. The surfactant blend in ether is infused through the 14-measure needle into a fluid arrangement of material. Vaporization of ether prompts the arrangement of single-layered vesicles. The molecule size of the niosomes shaped relies upon the conditions utilized the distance across of the vesicle range from 50 to 1000 nm.

Handshaking strategy (meager film hydration method):

In this technique, the surfactant and cholesterol are broken up in an unstable natural dissolvable, (for example, diethyl ether, chloroform, or methanol) in a round base flagon. The natural dissolvable is eliminated at room temperature (20°C) utilizing a rotating evaporator leaving a slim layer of strong combination kept on the mass of the cup. The dried surfactant film can be rehydrated with a watery stage at 0-60°C with delicate unsettling to yield multilamellar niosomes.

Sonication Method

In this strategy, an aliquot of drug arrangement in the cushion is added to the surfactant/cholesterol blend in a 10-ml glass vial. The blend is test sonicated at 60°C for 3 minutes utilizing a sonicator with a titanium test to yield niosomes.

Micro fluidization strategy

Micro fluidization is a new procedure used to prepare unilamellar vesicles of defined size dissemination. This technique depends on the lowered fly rule in which two fluidized streams collaborate at ultra-high speeds, in exactly characterized miniature channels inside the cooperation chamber. The impingement of a slim fluid sheet along a typical front is masterminded to such an extent that the energy provided to the system stays inside the space of the niosomes arrangement. The outcome is a more prominent consistency, more modest size and better reproducibility of niosomes shaped.

Multiple film extrusion strategy

A combination of surfactant, cholesterol, and diacetyl phosphate in chloroform is made into a slight film by vanishing. The film is hydrated with watery drug polycarbonate layers, arrangement and the resultant suspension expelled through which are set in series for up to 8 sections. It is a decent strategy for controlling baneful size.

Reverse Phase Evaporation Technique (REV)

In this strategy, Cholesterol and surfactant (01:01) are broken down in a combination of ether and chloroform. A watery stage containing drug is added to this and the subsequent two stages are sonicated at 4-5°C. A reasonable gel is shaped which is further sonicated after the expansion of phosphate supported saline (PBS). The natural stage is taken out at 40°C under low tension. The subsequent thick pernicious suspension is weakened with PBS and warmed on a water shower at 60°C for 10 min to yield niosomes.

Transmembranes pH angle (inside acidic) Drug Uptake Process: or Remote Loading Technique

An answer of surfactant and cholesterol are disintegrated in chloroform. The dissolvable is then vanished under decreased strain to get a slender film on the mass of the round base flagon. This film is hydrated with 300mm citrus extract (PH 4.00) by vertex blending. The

subsequent multilamellar vesicles are frozen and shared multiple times and later sonicated. To this niosomal suspension, a watery arrangement containing 10 mg/ml of drug is added and vortexes. The PH of the example is then raised to 7.0-7.2 with 1M disodium phosphate. This blend is subsequently warmed at 60°c for 10 minutes to give niosomes.

- **Bubble Method**

The gurgling unit comprises a round-lined carafe with three necks, and this is situated in a water shower to control the temperature. Water-cooled reflux and thermometer are situated in the first and second neck and nitrogen supply through the third neck. Cholesterol and surfactant are scattered together in this cushion (PH 7.4) at 70°C, the scattering blended for 15 seconds with a high shear homogenizer and quickly a while later "rose" at 70°C utilizing nitrogen gas to yield niosomes.

- **Measurement of Angle of repose**

It measures dry niosomes powder was estimated by a pipe technique. The niosomes powder has filled a pipe which was fixed at a position with the goal that the 13mm outlet hole of the pipe is 5cm over a level dark surface. The powder streams down from the channel to frame a cone on a superficial level and the point of rest was then determined by estimating the stature of the cone and the width of its base.

- **SEM**

The particle size of niosomes is a very important trademark. The surface morphology (roundness, perfection, and development totals) and the size circulation of niosomes were concentrated by Scanning Electron Microscopy (SEM). Niosomes were sprinkled onto the twofold-sided tape that was attached to aluminum hits. The aluminum stub was put in the vacuum office of a checking electron magnifying instrument (XL 30 ESEM with EDAX, Philips, Netherlands). The examples were noticed for morphological portrayal utilizing a vaporous optional electron finder (working pressing factor: 0.8 torr, speed increase voltage: 30.00 KV) XL 30, (Philips, Netherlands).

- **Optical Microscopy**

The niosomes were mounted on glass slides and saw under a magnifying instrument (Medilux-207RII, Kyowa-Getner, Ambala, India) with amplification of 1200X for morphological perception after reasonable weakening.

The photomicrograph of the arrangement is likewise acquired from the magnifying lens by utilizing a computerized SLR camera.

Estimation of vesicle size

Vesicle scatterings were weakened multiple times in a similar medium utilized for their arrangement. Vesicle size was estimated on a molecule size analyzer (Laser diffraction molecule size analyzer, Sympatec, Germany). The mechanical assembly comprises of a He-Ne laser light emission nm centered with a base force of 5 mW utilizing a Fourier focal point [R-5] to a point at the focal point of multielement identifier and a little volume test holding cell (Su cell). The example was blended utilizing a stirrer before deciding the vesicle size. He announced that the normal molecule size of niosomes inferred niosomes is around 6µm while that of customary niosomes is about 14µm.

Entrapment Productivity

Entrapment proficiency of the niosomal scattering should be possible by isolating the unentrapped drug by dialysis centrifugation or gel filtration as depicted above and the drug remained entangled in niosomes is dictated by complete vesicle interruption utilizing half n-propanol or 0.1% Triton X-100 and investigating the resultant arrangement by fitting measure strategy for the drug. Where,

Osmotic Pressure

Adjustment of the vesicle size can be dictated by osmotic examinations. Niosomes definitions are brooded with hypotonic, isotonic, hypertonic answers for 3 hours. Then, at that point, the changes in the size of vesicles in the definitions are seen under optical microscopy.

Stability studies

To decide the security of niosomes, the upgraded cluster was put away in water/airproof fixed vials at various temperatures. Surface attributes and rate drug held in niosomes and niosomes got from proniosomes were chosen as boundaries for assessment of the solidness, since shakiness of the definition would reflect in drug spillage and a diminishing. In the rate drug held. The niosomes were tested at normal timespans (0,1,2, and 3months), noticed for shading change, surface qualities, and tried for the rate drug held after being hydrated to shape niosomes and examined by reasonable logical methods (UV spectroscopy, HPLC techniques, and so on).

Zeta possible investigation

Zeta potential examination is accomplished for deciding the colloidal properties of the pre-arranged plans. The reasonably weakened niosomes got from pronoisome not settled utilizing zeta potential analyzer dependent on electrophoretic light dissipating and laser Doppler velocimetry strategy. The temperature was set at 25°C. Charge on vesicles and their mean zeta possible qualities with a standard deviation of estimations were gotten straightforwardly from the estimation.

APPLICATIONS [32-36]

- Niosomes have been utilized for examining the idea of the resistant reaction incited by antigens.
- It is utilized as Drug Targeting.
- It is utilized as an Anti-neoplastic Treatment for example Malignant growth Disease.
- It is utilized as Leishmaniasis for example Dermal and Mucocutaneous diseases for example Sodium stibogluconate.
- Niosomes as Carriers for Hemoglobin.
- It is utilized go about as Delivery of Peptide Drugs.
- Niosomes can be utilized as a transporter for hemoglobin.
- It is utilized in Studying Immune Response.
- Transdermal Drug Delivery Systems Utilizing Niosomes.
- It is utilized in ophthalmic drug delivery.
- Niosomal system can be utilized as symptomatic specialists.

Immunological use of niosomes

Niosomes have been utilized for contemplating the idea of the safe reaction incited by antigens. Niosomes can likewise be used for focusing on drugs to organs other than the Reticulo-Endothelial System. A transporter system (like antibodies) can be joined to

niosomes (as immunoglobulin's tight spot promptly to the lipid surface of the niosome) to target them to explicit organs.

- **Sustained Release**

The supported delivery activity of niosomes can be applied to drugs that have low restorative files and have low solvency with water since those could be kept up within the dissemination through niosomal encapsulation.

- **Restricted Drug Action**

Drug delivery through niosomes is one of the ways to deal with accomplish limited drug activity since their size and low vulnerability through the epithelium and connective tissue keeps the drug restricted at the site of the organization.

- **Niosomes as Drug Carriers**

Niosomes have additionally been utilized as transporters for iobitridol, asymptomatic specialists utilized for X-beam imaging. Skin niosomes may fill in as solubilization framework, as a nearby stop for supported arrival of dermally dynamic accumulates, as infiltration enhancers, or as rate-restricting layer hindrance for the adjustment of systemic assimilation of drugs.

- **Transdermal delivery of drugs by niosomes**

Those drugs have slow infiltration of medicament through the skin is the significant disadvantage of the transdermal course of delivery. An expansion in the infiltration rate has been accomplished by transdermal delivery of drugs fused in niosomes. From the above talked about investigations, and confocal microscopy, it was seen that non-ionic vesicles could be formed to target pilosebaceous organs. Skin niosomes may fill in as solubilization network, as a nearby station for supported arrival of dermally dynamic builds, as infiltration enhancers, or as rate-restricting layer obstruction for the balance of systemic retention of drugs.

- **Leishmaniasis**

Leishmaniasis is an infection where a parasite of the family Leishmania attacks the cells of the liver and spleen. Utilization of niosomes in tests directed showed that it was feasible to

control more elevated levels of the drug without the setting off of the incidental effects, and accordingly permitted more noteworthy adequacy in treatment.

- **Delivery of Peptide Drugs**

Oral peptide drug delivery has for some time been confronted with a test of bypassing the proteins which would break down the peptide. The utilization of niosomes to effectively shield the peptides from gastrointestinal peptide breakdown is being examined. In an in vitro study led by oral delivery of a vasopressin subsidiary captured in niosomes showed that ensnarement of the drug fundamentally expanded the solidness of the peptide.

Niosome plan as a mind-designated delivery system for the vasoactive digestive peptide Radiolabelled (I125) VIP-loaded glucose bearing niosomes was infused intravenously to mice. Epitomized VIP inside glucose-bearing niosomes displays higher VIP cerebrum take-up when contrasted with control.

- **Niosomes as transporters for Hemoglobin**

Niosomes can be utilized as a transporter for hemoglobin. Niosomal suspension shows an apparent range superimposable which is probably going to be or, onto that of free hemoglobin. Vesicles are porous to oxygen and hemoglobin separation bend can be changed comparably to non-epitomized hemoglobin. Hostile to neoplastic Treatment Most antineoplastic drugs cause extreme incidental effects. Niosomes can modify the digestion; draw outflow and half the existence of the drug, accordingly diminishing the symptoms of the drugs. Niosomes are the diminished pace of expansion of cancer and higher plasma levels joined by more slow disposal.

- **Drug Targeting**

Quite possibly the most helpful part of niosomes is their capacity to target drugs. Niosomes can be utilized to target drugs to the reticuloendothelial system. The reticuloendothelial system (RES) especially takes up niosome vesicles. The take-up of niosomes is constrained by flowing serum factors called opsonins. These opsonins mark the niosome for leeway. Such a limitation of drugs is used to treat cancers in creatures known to metastasize to the liver and spleen. This confinement of drugs can likewise be utilized for treating parasitic contaminations of the liver. Niosomes can likewise be used for focusing on drugs to organs other than the RES. A transporter system (like antibodies) can be joined to niosomes (as

immunoglobulin's tight spot promptly to the lipid surface of the niosome) to target them to explicit organs.

CONCLUSION

Niosomal drug delivery system is perhaps the best illustration of incredible advancement in drug delivery advances and nanotechnology. Clearly, niosome has all the earmarks of being an all-around favored drug delivery system over other dose structures as niosome is generally stable in nature and monetary. There is parcel of extension to typify harmful enemy of malignant growth drugs, against infective drugs, enemies of AIDS drugs, calming drugs, hostile to viral drugs, and so on in niosomes and to utilize them as promising drug transporters to accomplish better bioavailability and focusing on properties and for diminishing the poisonousness and symptoms of the drugs. Consequently, these regions require further systemic thought and exploration to bring out monetarily and important accessible niosomal readiness. The idea of joining the drug into or niosomes for a superior focusing of the drug at proper tissue objective is broadly acknowledged by specialists and academicians. The ionic drug transporters are generally harmful and unacceptable though niosomal transporters are more secure. Furthermore, taking care of and capacity of niosomes require no uncommon conditions. Niosomes address a promising drug delivery module. They have comparable construction to liposomes, to minimal same in property and consequently, they can address elective vesicular systems regarding liposomes, due to the niosome capacity to embody diverse kinds of drugs inside their multi-natural design. Niosomes are musings to be better competitor drug delivery when contrasted with liposomes because of different variables like expense, solidness and so forth Niosomes have a vital and key job in different kinds of drug conveyances; like focusing on, skin, ophthalmic and parenteral. Niosomes are exceptionally helpful in the brilliant future of pharma ventures. So far just creature experimentation of this designated drug delivery system is accounted for yet further clinical examinations in human volunteers, pharmacological and toxicological examinations in creatures and human volunteers might assist with taking advantage of niosomes as prosperous drug transporters for focusing on drugs all the more proficiently, for treating malignancy, contamination and AIDS and so on.

REFERENCES

1. Shakya V. Niosomes: A Novel Trend in Drug Delivery. Ijrdp. 2014; 3: 1036- 1041.
2. Makeshwar K, Wasankar S. Niosomes: a novel drug delivery system. Asian J. Pharm. Res. 2013; 3: 16-20.
3. Punithavalli G, Vignesh M. Formulation of Niosomal Suspension with enhanced oral bioavailability of Diclofenac sodium. Journal of Global Trends in Pharmaceutical Sciences. 2012; 3: 656-671.
4. Katare R, Gupta P, Mahor S, Rawat A, Khatri K, Katare Y, Panda A, Vyas S. Development of polysaccharide-capped niosomes for oral immunization of tetanus toxoid. Journal Drug Del. Sci. Tech. 2006; 16: 167-172.
5. Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. Journal of Pharm. Pharmaceut. Sci. 2002; 5: 220-225.
6. Bagheri A, Chu B, Yaakob H. Niosomal Drug Delivery Systems: Formulation, Preparation and Applications. World Applied Sciences Journal. 2014; 32: 1671-1685.
7. Sudheer P, Kaushik K. Review on Niosomes- A Novel Approach For Drug Targeting, Journal of Pharmaceutical Research. 2015; 1-14.
8. Sunilkumar M. Niosomes As novel drug delivery system. International Research Journal of Pharmaceutical and Applied Science. 2015; 5: 1-7.
9. Sankhyan A, Pawar P. Recent Trends in Niosome as Vesicular Drug Delivery System. Journal of Applied Pharmaceutical Science. 2012; 2: 20-32.
10. Gurjar P. Niosome: A Promising Pharmaceutical Drug Delivery. Int. J. Pharm Anal. 2014; 2: 425-431.
11. Austin Pharmacol Pharm 3(2): id1016 (2018) - Page - 06
12. Madhav N, Saini A. Niosomes: A novel drug delivery system. International journal of research in pharmacy and chemistry. 2011; 1: 498-511.
13. Khandare JN., Madhavi G., Tamhankar BM., Niosomes Novel Drug Delivery System. The Eastern Pharmacist. 1994, 37: 61-64.
14. Weissman G, Bloomgarden D, Kaplan R, Cohen C, Hoffstein S, Collins T, et al. A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells. Proc Natl Acad Sci 1975;72:88-92.
15. Navneet Kumar Verma, Asha Roshan. Niosomes and its application:A Review, IJRPLS, 2014; 2(1): 182-184.
16. Breimer DD and Speiser R. Topics in Pharmaceutical Sciences. Elsevier Science Publishers, New York, USA. 1985;291.
17. Handjani VRM. Dispersion of Lamellar Phases of Nonionic Lipids in Cosmetic Products. Int J Cosmetic Sc. 1979;30.
18. Baillie A, Florence A, Hume L, Muirhead G, Rogerson A. The preparation and properties of niosomes non-ionic surfactant vesicles. J. Pharm. Pharmacol. 1985; 37: 863-868.
19. Debnath A, Kumar A. Structural and Functional significance of Niosome and Proniosome in Drug Delivery System. International Journal of Pharmacy and Engineering. 2015; 3: 621-637.
20. Jindal K. Niosomes as a Potntial Carrier System: A Review. IJPCBS. 2015; 5: 947-959.
21. Kaur H, Dhiman S, Arora S. Niosomes: A novel drug delivery system. Int. J. Pharm. Sci. Rev. Res. 2012; 15: 113-120.
22. Navya M. Niosomes As novel vesicular drug delivery system- A review. Asian Journal of Research in Biological and Pharmaceutical Sciences. 2014; 2: 62- 68.
23. Verma N. Niosomes and Its Application -A Review. IJRPLS. 2014; 2: 182- 184.
24. Sharma S. Span-60 Niosomal Oral Suspension of Flucanazole: Formulation and in vitro evaluation. Asian journal of pharmaceutical research and health care. 2009; 1: 142-156.
25. Suzuki K, Sokan K. The Application of Liposomes to Cosmetics. Cosmetic and Toiletries. 1990; 105: 65-78.
26. Tabbakhian M, Tavakoli N, Jaafari M, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes. Int. J. Pharm. 2006; 323: 1-10.
27. Namdeo A, Jain N. Niosomes as drug carriers. Indian Journal of Pharm. Sci. 1996; 58: 41-46.
28. Rai A. Niosomes: An approach to current drug delivery-A Review. International Journal of Advances in Pharmaceutics. 2017; 06: 41-48.

29. Srivastav A, Das P. To Study the Formulation of Niosome of Ofloxacin and Its Evaluation for Efficacy of Anti-Microbial. International Journal of Innovative Research in Science, Engineering and Technology. 2014; 3: 17958-17965.
30. Mishra N, Srivastava V, Kaushik A, Chauhan V, Srivastava G. Formulation and in vitro- evaluation of Niosomes of Aceclofenac. JSIR. 2014; 3: 337-341.
31. Bayindir Z, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. Journal of Pharmaceutical Sciences. 2010; 99: 2049-2060.
32. Talegaonkar S., Misra PR., Khar RK., Vesicular systems: An overview. Indian J. Pharm. Sci. 2006, 68: 141-153.
33. Ijeoma F., Uchegbu., Suresh P., Vyas., Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm. 1998; 172: 33–70.
34. Malhotra M., Jain N.K., Niosomes as Drug Carriers. Indian Drugs. 1994, 31(3): 81-866.
35. Alsarra A., Bosela A,, Ahmed S.M,, Mahrous G.M., Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. And Biopharm. 2004; 2(1): 1-6.
36. Hu C., Rhodes D.G., Proniosomes: a novel drug carrier preparation. Int. J. Pharm. 1999, 185: 23-35.